Regulator Warns Of Tougher Pricing Regime In India Amid ‘Market Failure’
Executive Summary
India’s apex pricing authority concludes some in Rx industry have not played 'fair'; 25% of products show market failure, Bhupendra Singh says.
You may also be interested in...
India Cuts Prices Of 463 Anticancers But Loose Ends Remain
Prices of over 400 anticancers have been revised downwards in India by the capping of trade margins, but some healthcare activists say that real benefits for patients could still be elusive. Pharma is also required to maintain production volumes in the new scenario – will it pinch?
Pharma Counters India Competition Commission On ‘Market-Distorting’ Practices
A note by the Competition Commission of India has put the spotlight back on certain pharma industry practices that are seen as triggering non-competitive market outcomes. Pharma has called into question certain claims of the CCI, with some experts suggesting that the regulator may have also exceeded its remit.
Pharma Counters India Competition Commission On ‘Market-Distorting’ Practices
A note by the Competition Commission of India has put the spotlight back on certain pharma industry practices that are seen as triggering non-competitive market outcomes. Pharma has called into question certain claims of the CCI, with some experts suggesting that the regulator may have also exceeded its remit.